A review of more recent evidence led to slightly updated guidance on medication treatment, with the three AChE inhibitors (donepezil, galantamine and rivastigmine) recommended as options for managing mild‐to‐moderate Alzheimer's disease (AD) and memantine recommended as an option for people with moderate AD who are intolerant of or have a contraindication to AChE inhibitors or with severe AD (National Institute for Health and Care Excellence 2016). This evidence concerns the gene ACHE and Alzheimer disease.